BioSpace News Archive

INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world’s only in vivo Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, will report financial results for its third quarter 2021, ended September 30, 2021, after the market close on Monday, November 15, 2021.

Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring systems for people with diabetes, reported financial results for the quarter ended September 30, 2021.

Neovasc, Inc.(“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the third quarter ended September 30, 2021.

Mirati Therapeutics, Inc. a clinical-stage oncology company, announced that it intends to offer and sell in an underwritten public offering $500 million of shares of its common stock.

Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted one new employee options to purchase a total of 28,000 shares of the Company’s common stock at an exercise price per share of $34.74, which was the closing price on November 8, 2021.

IMV Inc. today announced that translational data from the Phase 2 clinical study in patients with advanced, recurrent ovarian cancer will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.

MAIA Biotechnology, Inc. Announces Poster Presentation at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC)

Rubius Therapeutics, Inc. announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will provide a corporate update at the Jefferies London Healthcare Conference via a virtual presentation, which will be available to view on the conference website on November 18-19, 2021.

BioInvent International AB and Transgene announce preclinical data supporting the mode of action of BT-001, their novel dual mechanism-of-action oncolytic Vaccinia Virus.

Dyadic International, Inc., a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines, therapeutics and other protein based products announced the appointment of Joe Hazelton as Chief Business Officer, effective immediately.